ReviewFrontiers in oncology2026
Benmelstobart+anlotinib: an emerging therapeutic option in the targeted-immunotherapy era.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, with the gradual deepening of research, basic and clinical studies on targeted-immunotherapy combination regimens have flourished and yielded exciting results. The novel programmed cell death ligand 1 (PD-L1) inhibitor benmelstobart in combination with the targeted agent anlotinib demonstrates synergistic antitumor effects, achieving a synergy therapeutic outcome. This article focuses on the mechanisms underlying the combined action of "benmelstobart+anlotinib", summarizes the currently approved indications and clinical research progress, and aims to provide alternative therapeutic options for patients with malignant tumors as well as new insights for the development and selection of future combination treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.